Highest-materiality recent filing
CONMED appoints John E. Gallagher as CFO effective July 15, 2026
Gallagher joins from Certara (CFO); previously CFO at Cue Health and SVP/CFO at BD Medical Segment.
CONMED repurchases $645M of 2.25% convertible notes due 2027 for $637M cash
Principle amount of $645.2M at 2.25% coupon due 2027 acquired for $637.2M in cash.
CONMED secures $450M incremental term loan facility to repurchase convertible notes due 2026
Aggregate $450M in incremental delayed draw term A-2 loans available for single draw on or before June 14, 2026.
CONMED appoints two new directors from J&J and Boston Scientific; Board expands to nine
Appointed Celine Martin (ex-J&J MedTech exec) and Jeff Mirviss (ex-Boston Scientific exec) to Board, effective July 1, 2026.
CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance
Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.
CONMED names VP & Corporate Controller Andrew Moller as Interim Principal Financial Officer
Andrew Moller, 51, appointed Interim Principal Financial Officer effective March 15, 2026.
CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS
Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.
CONMED provides preliminary 2026 guidance at J.P. Morgan Healthcare Conference; no figures in filing
Presented at J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026.
CONMED CFO Todd Garner to depart; transition to Special Advisor through Nov 2026
Garner's separation effective by Mar 15, 2026 or upon appointment of new CFO; he will serve as Special Advisor until Nov 2, 2026.
CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026
Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.
CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback
Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.
CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025
Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.
CONMED declares $0.20 quarterly dividend, payable Oct 3, 2025
Quarterly cash dividend of $0.20 per share declared on August 7, 2025.
CONMED Q2 adj EPS $1.15 beats; raises FY2025 revenue and adj EPS guidance
Q2 sales $342.3M (+3.1% YoY); GAAP EPS $0.69 (down from $0.96), adj EPS $1.15 (up from $0.98).
CONMED director Martha Aronson resigns to become Merit Medical President & CEO
Martha Aronson resigned from CONMED board effective July 7, 2025 to become President and CEO of Merit Medical Systems.
CONMED enters into $750M credit agreement; maturities extended to 2030
New $550M USD revolver, $100M multicurrency revolver, and $100M term loan; maturity date June 10, 2030.
CONMED declares $0.20 dividend; shareholders approve 2025 LTIP and reelect directors
Quarterly cash dividend of $0.20/share declared, payable July 3, 2025 to holders of record June 13, 2025.
CONMED Q1 adjusted EPS $0.95, revenue $321.3M, raises FY2025 guidance
Total sales $321.3M, up 2.9% reported (3.8% constant currency); domestic +4.2%, international +1.2%.
CONMED appoints Andrew Moller as Principal Accounting Officer effective April 1, 2025
Andrew Moller, 50, appointed Principal Accounting Officer; joined as VP Corporate Controller on Jan 27, 2025.
CONMED appoints Mark Kaye as director; declares $0.20 quarterly dividend
Board expanded to nine; Mark Kaye appointed effective Feb 24, 2025, with Audit and Strategy committee assignments.
CONMED Q4 2024 sales $345.9M (+5.8% YoY), adjusted EPS $1.34; FY25 guidance issued
Q4 GAAP diluted EPS $1.08 (vs $1.05 YoY); adjusted diluted EPS $1.34 (+26.4%).
Investor presentation for the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
CONMED declares $0.20 quarterly dividend payable Jan 3, 2025
Quarterly cash dividend of $0.20 per share declared on December 9, 2024.
CONMED Q3 2024: adj. EPS $1.05 beats; revenue guidance trimmed; CEO transition to Beyer Jan 2025
Sales $316.7M (+4.0% YoY); GAAP EPS $1.57 (vs $0.50); adjusted EPS $1.05 (+16.7%).
CONMED prelim Q3 rev $315-318M; adj EPS growth to exceed 9-11% guide
Revenue expected $315M-$318M for Q3 2024 (preliminary).
Manufacturing facility in Largo, FL and distribution center in Lithia Springs, GA were impacted.
CONMED Corp corporate controller leaving Sept 27; interim and accounting officer changes
Eric B. Staves, VP Corporate Controller, departs Sept 27 for an executive opportunity elsewhere.
CONMED President Bill Peters to depart on August 31, 2024
Employment of Stanley W. (Bill) Peters, President of Advanced Surgical & Advanced Endoscopic Technologies, terminates Aug 31, 2024.
CONMED declares $0.20 quarterly dividend, payable Oct 4, 2024
Quarterly cash dividend of $0.20 per share declared on August 9, 2024.
CONMED Q2 adj EPS $0.98 beats; cuts FY revenue & EPS guidance on supply chain delays
Revenue $332.1M (+4.5% reported, +5.2% constant currency); GAAP EPS $0.96 vs $0.43; adj EPS $0.98 vs $0.83 (+18.1%).
CONMED announces retirement of VP Corporate Controller Berge, promotion of Staves
Terence M. Berge to retire as VP, Corporate Controller effective June 30, 2024, then serve as Special Advisor.
CONMED declares $0.20 quarterly dividend payable July 5, 2024
Quarterly cash dividend of $0.20 per share declared on May 22, 2024.
GAAP diluted EPS $0.63 vs $0.06 in Q1 2023; adjusted EPS $0.79, up 19.7% YoY.
CONMED promotes Pat Beyer to COO; Heather Cohen transitions to Special Advisor
Pat Beyer promoted to COO effective Apr 24, 2024; salary £478,225, 80% STIP target, $800k one-time equity grant (75% options, 25% PSUs).
CONMED declares quarterly dividend of $0.20 per share
Board declared quarterly cash dividend of $0.20 per share.
CONMED Q4 sales $327M (+30.4% YoY); adjusted EPS $1.06 (+152%); guides FY24 rev $1.34-1.365B
Q4 sales $327.0M, +30.4% YoY (31.5% constant currency); domestic +33.3%, intl +26.5% as reported.
CONMED declares $0.20 quarterly dividend payable Jan 5, 2024
Quarterly cash dividend of $0.20 per share declared on December 4, 2023.
CONMED Q3 sales $304.6M (+10.7% YoY); adj. EPS $0.90 (+16.9%); raises FY guidance
Revenue of $304.6M, +10.7% reported (+11.9% constant currency). Domestic +9.5%, International +12.3%.
CONMED declares $0.20 quarterly dividend payable Oct 5, 2023
Quarterly cash dividend of $0.20 per share announced on August 10, 2023.
CONMED Q2 sales +14.6% to $317.7M, adj. EPS $0.83, raises FY guidance
GAAP diluted EPS $0.43 vs loss of $5.65; adjusted diluted EPS $0.83, +9.2% YoY.
CONMED declares $0.20 quarterly dividend payable July 5, 2023
Quarterly cash dividend of $0.20 per share declared; payable July 5, 2023 to holders of record June 15, 2023.
CONMED Q1 sales $295.5M (+21.9% YoY); raises FY 2023 revenue and EPS guidance
Sales $295.5M (+21.9% as reported; +25.1% constant currency); acquisitions contributed ~570 bps growth.
CONMED declares $0.20 quarterly dividend, payable April 5, 2023
Quarterly cash dividend of $0.20 per share declared.
CONMED reports Q4 sales down 8.4%, adj. EPS down 60.7% on warehouse software disruption
Q4 sales $250.9M (-8.4% YoY); GAAP EPS $0.86 vs $0.75 YoY; adjusted EPS $0.42 vs $1.07.
CONMED amends credit agreement to replace LIBOR with Term SOFR benchmark
Third Amendment to Seventh Amended and Restated Credit Agreement, dated Dec. 20, 2022.
CONMED GC Daniel Jonas to retire by July 2026; Heather Cohen succeeds
General Counsel Jonas transitions to Special Counsel & Corporate Secretary; retirement set for July 1, 2026.
CONMED declares quarterly dividend of $0.20 per share payable Jan 5, 2023
Dividend of $0.20 per common share declared.
CONMED withdraws FY2022 outlook due to warehouse software disruption; provides FY2023 guidance
Service level disruptions from new warehouse software impacted Q4 shipments; backlog peaked at $35M, now $28M.
CONMED Q3 sales $275.1M (+10.6% YoY); adjusted EPS $0.77 misses prior year; narrows 2022 guidance
Sales $275.1M +10.6% as reported, +12.1% constant currency; domestic +14.2%, international +6.2% as reported.
CONMED declares $0.20 quarterly dividend, payable Oct 5 to holders of record Sep 15
Quarterly cash dividend of $0.20 per share declared.
On June 17, 2026, CONMED Corporation (the “Company”) announced that John E. Gallagher has been appointed to serve as the Company’s Executive Vice President, Chief Financial Officer beginning July 15, 2026 (the “Effective Date”).
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
On May 19, 2026, the Board appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer of the Company effective June 1, 2026.
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
On April 1, 2025, Mr. Moller was appointed Principal Accounting Officer
and Todd W. Garner, Executive Vice President of Finance and Chief Financial Officer, ceased serving in the role of Principal Accounting Officer.
Kimberly A. Lockwood, who was acting as Interim Corporate Controller, has been promoted to Senior Director of Financial Reporting.
On February 24, 2025, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Mark Kaye as a director effective immediately.
effective as of October 31, 2024, Curt R. Hartman’s service as Chair of the Board will cease
Commencing on March 3, 2025 (the 'Transition Date'), Mr. Hartman will serve as a Special Advisor
As of the Separation Date, Mr. Hartman’s service relationship with the Company will cease.
Effective as of January 1, 2025, Mr. Hartman will transition into a non-executive officer role
Max materiality 0.85 · Median 0.53 · Most common event earnings